

## **Supporting information**

*Article*

# **Synthesis and Bioactivity of Hydrazide-hydrazone of 1-Adamantyl-carbonyl Moiety**

**Hien Pham Van<sup>1</sup>, Dung Phan Thi Phuong<sup>2</sup>, Chau Phan Dinh<sup>3,\*</sup> and Duong Vu Binh<sup>1,\*</sup>**

<sup>1</sup> Drug R&D center, Vietnam Military Medical University. No.160, Phung Hung str., Phuc La ward, Ha Dong district, Hanoi 100000, Vietnam.

<sup>2</sup> Department of Pharmaceutical Chemistry, Hanoi University of Pharmacy. No. 15, Le Thanh Tong Str., Hoan Kiem district, Hanoi 100000, Vietnam.


<sup>3</sup> Hanoi University of Science and Technology. No.1, Dai Co Viet str., Bach Khoa ward, Hai Ba Trung district, Hanoi 100000, Vietnam.

\*Correspondence: [vbduong2978@gmail.com](mailto:vbduong2978@gmail.com) and [chau.phandinh@hust.edu.vn](mailto:chau.phandinh@hust.edu.vn);  
Tel.: +84 983 425 460; Fax: +84 243 688 4077.

## Table of content

<b>Scheme 1.</b> Synthesis of hydrazide hydrazone <b>4a-i</b> and <b>5a-k</b> .....	1
<b>Table 1.</b> Crystal solvent (Cryst. Solv.), melting point (m.p), yield (%), molecular formulae, molecular weight (Mol. Wt.) and Rf of hydrazide-hydrazone <b>4a-i</b> and <b>5a-k</b> .....	2
<b>Table 2.</b> MIC of synthesized hydrazide-hydrazole <b>4a-i</b> and <b>5a-k</b> .....	3
<b>Table 3.</b> IC <sub>50</sub> of synthesized hydrazide-hydrazole <b>4a-i</b> and <b>5a-k</b> .....	4
<b>Table 4.</b> The effect of newly synthesized hydrazide-hydrazole <b>4a-i</b> and <b>5a-k</b> on the viability of HeP3B, Hela, A549 and MCF-7 cell after 48 h of incubation .....	5
<sup>1</sup> H-NMR spectrum of compound <b>4a</b> .....	6
<sup>13</sup> C-NMR spectrum of compound <b>4a</b> .....	6
HMBC spectrum of compound <b>4a</b> .....	7
HSQC spectrum of compound <b>4a</b> .....	7
ESI-MS spectrum of compound <b>4a</b> (negative) .....	8
ESI-MS spectrum of compound <b>4a</b> (positive) .....	8
<sup>1</sup> H-NMR spectrum of compound <b>4b</b> .....	9
ESI-MS spectrum of compound <b>4b</b> (negative).....	9
ESI-MS spectrum of compound <b>4b</b> (positive).....	10
<sup>1</sup> H-NMR spectrum of compound <b>4c</b> .....	10
ESI-MS spectrum of compound <b>4c</b> (negative).....	11
<sup>1</sup> H-NMR spectrum of compound <b>4d</b> .....	11
ESI-MS spectrum of compound <b>4d</b> (negative).....	12
ESI-MS spectrum of compound <b>4d</b> (positive) .....	12
<sup>1</sup> H-NMR spectrum of compound <b>4e</b> .....	13
ESI-MS spectrum of compound <b>4e</b> (negative) .....	13
ESI-MS spectrum of compound <b>4e</b> (positive) .....	14
<sup>1</sup> H-NMR spectrum of compound <b>4f</b> .....	14
ESI-MS spectrum of compound <b>4f</b> (positive).....	14
<sup>1</sup> H-NMR spectrum of compound <b>4g</b> .....	15
ESI-MS spectrum of compound <b>4g</b> (positive) .....	15
<sup>1</sup> H-NMR spectrum of compound <b>4h</b> .....	16
ESI-MS spectrum of compound <b>4h</b> (positive).....	16
<sup>1</sup> H-NMR spectrum of compound <b>4i</b> .....	17
ESI-MS spectrum of compound <b>4i</b> (positive) .....	18
<sup>1</sup> H-NMR spectrum of compound <b>5a</b> .....	18
ESI-MS spectrum of compound <b>5a</b> (negative) .....	18
ESI-MS spectrum of compound <b>5a</b> (positive) .....	19
<sup>1</sup> H-NMR spectrum of compound <b>5c</b> .....	20
ESI-MS spectrum of compound <b>5c</b> (positive).....	20
<sup>1</sup> H-NMR spectrum of compound <b>5e</b> .....	21
ESI-MS spectrum of compound <b>5e</b> (negative) .....	21
ESI-MS spectrum of compound <b>5e</b> (positive) .....	22
<sup>1</sup> H-NMR spectrum of compound <b>5i</b> .....	22
ESI-MS spectrum of compound <b>5i</b> (positive) .....	22
<sup>1</sup> H-NMR spectrum of compound <b>5j</b> .....	23
ESI-MS spectrum of compound <b>5j</b> (negative) .....	23
ESI-MS spectrum of compound <b>5j</b> (positive) .....	24
<sup>1</sup> H-NMR spectrum of compound <b>5k</b> .....	24
ESI-MS spectrum of compound <b>5k</b> (positive) .....	25

*Scheme 1.* Synthesis of hydrazide hydrazone **4a-i** and **5a-k**



**Table 1.** Crystal solvent (Cryst. Solv.), melting point (m.p), yield (%), molecular formulae, molecular weight (Mol. Wt.) and Rf of hydrazide-hydrazone **4a-i** and **5a-k**.

Comp. No.	R1	R2	Cryst. Solv.	m.p (°C)	Yield (%)	Molecular Formula (Mol. Wt.)	TLC* (Rf)
4a	H	4-OH	EtOH	252.5-254.1	30.6	C <sub>19</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> (312.41)	0.36
4b	H	4-NO <sub>2</sub>	EtOH	226.0-227.6	60.5	C <sub>19</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub> (341.41)	0.58
4c	H	4-OC <sub>2</sub> H <sub>5</sub>	EtOH	159.5-160.6	32.2	C <sub>21</sub> H <sub>28</sub> N <sub>2</sub> O <sub>2</sub> (340.47)	0.57
4d	3-NO <sub>2</sub>	4-OCH <sub>3</sub>	EtOH	182.0-184.1	33.0	C <sub>20</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub> (371.44)	0.44
4e	3-NO <sub>2</sub>	4-Cl	EtOH	188.2-189.3	26.2	C <sub>19</sub> H <sub>22</sub> ClN <sub>3</sub> O <sub>3</sub> (375.85)	0.56
4f	H	4-Br	EtOH	190.7-191.0	29.0	C <sub>19</sub> H <sub>23</sub> BrN <sub>2</sub> O (375.31)	0.62
4g	H	4-OCH <sub>3</sub>	EtOH	171.6-173.0	30.0	C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O <sub>2</sub> (326.44)	0.52
4h	H	4-CH <sub>3</sub>	EtOH	179.5-180.4	37.3	C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O (310.44)	0.66
4i	H	H	EtOH	174.4-175.2	54.5	C <sub>19</sub> H <sub>24</sub> N <sub>2</sub> O (296.41)	0.59
5a	H	4-OH	EtOH	289.6-290.5	44.0	C <sub>18</sub> H <sub>22</sub> N <sub>2</sub> O <sub>2</sub> (298.39)	0.33
5c	H	4-OC <sub>2</sub> H <sub>5</sub>	EtOH	235.2-236.4	15.1	C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O <sub>2</sub> (326.44)	0.59
5e	3-NO <sub>2</sub>	4-Cl	EtOH	247.8-248.5	50.6	C <sub>18</sub> H <sub>20</sub> ClN <sub>3</sub> O <sub>3</sub> (361.83)	0.55
5i	H	H	EtOH	186.9-187.2	60.5	C <sub>18</sub> H <sub>22</sub> N <sub>2</sub> O (282.39)	0.54
5j	2-OH	5-CH <sub>3</sub>	EtOH	247.6-248.8	60.4	C <sub>19</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> (312.41)	0.57
5k	2-CH <sub>3</sub>	5-CH <sub>3</sub>	EtOH	283.5-284.0	35.5	C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O (310.44)	0.45

**Table 2.** MIC of synthesized hydrazide-hydrazole **4a-i** and **5a-k**

Comp. No.	MIC of synthesized compounds ( $\mu\text{M}$ )						
	Gram (+)			Gram (-)			Fungus
EF	SA	BC	EC	PA	SE	CA	
<b>4a</b>	12.5	12.5	12.5	-	-	-	12.5
<b>4b</b>	25	25	25	-	-	-	25
<b>4c</b>	25	25	25	-	-	-	25
<b>4d</b>	12.5	50	100	-	-	-	6.25
<b>4e</b>	25	50	50	-	-	-	25
<b>4f</b>	50	50	50	-	-	-	12.5
<b>4g</b>	25	25	100	-	-	-	25
<b>4h</b>	25	25	50	-	-	-	12.5
<b>4i</b>	25	50	50	-	-	-	25
<b>5a</b>	12.5	25	25	-	-	-	12.5
<b>5c</b>	12.5	50	100	-	-	-	12.5
<b>5e</b>	25	25	25	-	-	-	25
<b>5i</b>	50	50	50	-	-	-	50
<b>5j</b>	50	50	50	-	-	-	25
<b>5k</b>	25	25	25	-	-	-	25
STM	256 $\mu\text{g/mL}$	256 $\mu\text{g/mL}$	128 $\mu\text{g/mL}$	32 $\mu\text{g/mL}$	256 $\mu\text{g/mL}$	128 $\mu\text{g/mL}$	NT
CHM	NT	NT	NT	NT	NT	NT	32 $\mu\text{g/mL}$

EF: *Enterococcus faecalis* (ATCC13124); SA: *Staphylococcus aureus* (ATCC25923); BC: *Bacillus cereus* (ATCC 13245); EC: *Escherichia coli* (ATCC25922); PA: *Pseudomonas aeruginosa* (ATCC27853); SE: *Salmonella enterica* (ATCC12228); CA: *Candida albicans* (ATCC10231); STM: streptomycine; CHM: Cycloheximide; NT: not tested; - : inactive

**Table 3.** IC<sub>50</sub> of synthesized hydrazide-hydrazole **4a-i** and **5a-k**

Comp. No.	IC50 of synthesized compounds ( $\mu\text{M}$ )						Fungus CA
	Gram (+) EF	SA	BC	EC	PA	SE	
<b>4a</b>	6.35	6.77	6.12	-	-	-	6.37
<b>4b</b>	11.56	11.45	12.56	-	-	-	12.78
<b>4c</b>	13.24	12.67	12.77	-	-	-	13.11
<b>4d</b>	6.88	25.45	52.11	-	-	-	3.56
<b>4e</b>	13.55	25.11	25.99	-	-	-	13.57
<b>4f</b>	24.79	13.44	25.33	-	-	-	6.77
<b>4g</b>	12.56	12.55	56.7	-	-	-	11.55
<b>4h</b>	13.22	13.45	23.88	-	-	-	6.45
<b>4i</b>	12.56	25.66	25.65	-	-	-	12.33
<b>5a</b>	6.73	12.33	12.37	-	-	-	6.25
<b>5c</b>	6.77	26.55	26.78	-	-	-	6.66
<b>5e</b>	13.25	12.67	12.33	-	-	-	13.22
<b>5i</b>	25.66	26.55	26.56	-	-	-	25.33
<b>5j</b>	24.58	24.56	24.33	-	-	-	11.45
<b>5k</b>	12.35	12.45	12.33	-	-	-	13.46

EF: *Enterococcus faecalis* (ATCC13124); SA: *Staphylococcus aureus* (ATCC25923); BC: *Bacillus cereus* (ATCC 13245); EC: *Escherichia coli* (ATCC25922); PA: *Pseudomonas aeruginosa* (ATCC27853); SE: *Salmonella enterica* (ATCC12228); CA: *Candida albicans* (ATCC10231); - : inactive.


**Table 4.** The effect of newly synthesized hydrazide-hydrazole **4a-i** and **5a-k** on the viability of HeP3B, Hela, A549 and MCF-7 cell after 48 h of incubation

Comp. No.	Conc.	Hep3B	Hela	A549	MCF-7
<b>4a</b>	30 μM	63.89 ± 0.69	73.09 ± 2.31	67.78 ± 0.26	63.28 ± 1.41
	100 μM	56.53 ± 1.32	66.87 ± 1.10	51.63 ± 0.81	58.60 ± 0.32
<b>4b</b>	30 μM	66.83 ± 1.15	82.84 ± 1.37	66.89 ± 0.94	64.32 ± 2.92
	100 μM	56.49 ± 2.17	77.20 ± 0.90	62.26 ± 0.15	52.64 ± 2.02
<b>4c</b>	30 μM	80.62 ± 1.25	93.64 ± 0.88	77.76 ± 1.51	79.36 ± 1.40
	100 μM	72.74 ± 2.00	90.51 ± 1.28	70.20 ± 0.13	67.78 ± 0.95
<b>4d</b>	30 μM	96.80 ± 0.26	> 100	65.33 ± 1.28	90.20 ± 0.25
	100 μM	84.59 ± 2.39	86.34 ± 1.35	62.01 ± 2.37	78.82 ± 2.22
<b>4e</b>	30 μM	94.59 ± 2.20	80.07 ± 1.87	64.43 ± 0.49	60.94 ± 1.39
	100 μM	55.91 ± 1.70	44.37 ± 1.39	38.51 ± 1.59	38.69 ± 1.20
<b>4f</b>	30 μM	>100	88.26 ± 1.74	76.22 ± 0.98	94.68 ± 1.33
	100 μM	97.95 ± 2.43	83.18 ± 0.20	73.68 ± 1.03	91.27 ± 2.26
<b>4g</b>	30 μM	91.63 ± 2.63	96.61 ± 1.98	87.40 ± 0.95	83.11 ± 2.86
	100 μM	77.00 ± 1.84	79.46 ± 1.28	70.61 ± 1.66	71.75 ± 1.71
<b>4h</b>	30 μM	98.29 ± 2.46	> 100	78.42 ± 0.83	91.59 ± 2.29
	100 μM	75.83 ± 2.76	99.77 ± 1.89	68.99 ± 2.36	70.66 ± 2.57
<b>4i</b>	30 μM	81.96 ± 1.67	88.70 ± 1.79	68.43 ± 1.72	59.77 ± 2.41
	100 μM	80.7 ± 2.17	87.75 ± 0.29	67.73 ± 1.89	57.24 ± 0.75
<b>5a</b>	30 μM	87.03 ± 1.28	87.53 ± 0.21	69.08 ± 2.56	86.14 ± 0.49
	100 μM	68.89 ± 2.18	68.26 ± 2.02	50.78 ± 1.86	64.33 ± 1.76
<b>5c</b>	30 μM	88.96 ± 0.91	89.07 ± 1.21	90.47 ± 2.23	70.30 ± 1.23
	100 μM	78.97 ± 1.82	85.41 ± 1.34	81.32 ± 1.20	65.62 ± 0.64
<b>5e</b>	30 μM	57.77 ± 1.59	76.75 ± 1.07	36.42 ± 0.94	52.56 ± 0.75
	100 μM	37.78 ± 2.44	40.42 ± 0.38	19.62 ± 1.74	34.13 ± 2.22
<b>5i</b>	30 μM	83.16 ± 1.19	89.12 ± 2.43	79.49 ± 0.94	71.53 ± 1.64
	100 μM	74.90 ± 1.34	84.28 ± 2.12	55.22 ± 1.63	65.31 ± 1.66
<b>5j</b>	30 μM	92.80 ± 2.24	68.96 ± 2.38	78.71 ± 1.75	86.48 ± 2.08
	100 μM	85.71 ± 2.28	57.90 ± 1.35	59.18 ± 2.01	79.86 ± 2.13
<b>5k</b>	30 μM	98.51 ± 0.38	82.96 ± 0.59	62.55 ± 0.59	91.80 ± 0.35
	100 μM	83.34 ± 1.65	74.27 ± 1.67	52.39 ± 1.54	77.66 ± 1.54
<b>CPT*</b>	0.1 μg/mL	69.56 ± 1.27	57.06 ± 1.35	67.68 ± 1.88	56.68 ± 0.68
	5 μg/mL	37.65 ± 1.21	18.61 ± 0.56	26.74 ± 2.16	28.89 ± 1.07


\*Camptothecine.

Data is presented as percentage of the cell viability ± SD.


<sup>1</sup>H-NMR spectrum of compound 4a




<sup>13</sup>C-NMR spectrum of compound 4a




HMBC spectrum of compound 4a




HSQC spectrum of compound 4a




ESI-MS spectrum of compound **4a** (negative)




ESI-MS spectrum of compound **4a** (positive)




<sup>1</sup>H-NMR spectrum of compound **4b**




ESI-MS spectrum of compound **4b** (negative)




ESI-MS spectrum of compound **4b** (positive)




$^1H$ -NMR spectrum of compound **4c**




ESI-MS spectrum of compound **4c** (negative)




<sup>1</sup>H-NMR spectrum of compound **4d**




ESI-MS spectrum of compound **4d** (negative)




ESI-MS spectrum of compound **4d** (positive)




<sup>1</sup>H-NMR spectrum of compound **4e**




ESI-MS spectrum of compound **4e** (negative)




ESI-MS spectrum of compound **4e** (positive)




$^1H$ -NMR spectrum of compound **4f**




ESI-MS spectrum of compound **4f** (positive)




<sup>1</sup>H-NMR spectrum of compound **4g**




ESI-MS spectrum of compound **4g** (positive)




<sup>1</sup>H-NMR spectrum of compound 4h




ESI-MS spectrum of compound 4h (positive)




<sup>1</sup>H-NMR spectrum of compound **4i**




ESI-MS spectrum of compound **4i** (positive)




$^1\text{H-NMR}$  spectrum of compound **5a**




ESI-MS spectrum of compound **5a** (negative)




ESI-MS spectrum of compound **5a** (positive)




### <sup>1</sup>H-NMR spectrum of compound 5c




### ESI-MS spectrum of compound **5c** (positive)




<sup>1</sup>H-NMR spectrum of compound **5e**




ESI-MS spectrum of compound **5e** (negative)




ESI-MS spectrum of compound **5e** (positive)




$^1H$ -NMR spectrum of compound **5i**




ESI-MS spectrum of compound **5i** (positive)




<sup>1</sup>H-NMR spectrum of compound 5j




ESI-MS spectrum of compound 5j (negative)



ESI-MS spectrum of compound **5j** (positive)



<sup>1</sup>H-NMR spectrum of compound **5k**



ESI-MS spectrum of compound **5k** (positive)

